Clinical Trial

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)

Study acronym: OraGrowtH212
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goals of this single site trial are to study the pharmacokinetics (PK) and pharmacodynamics of LUM-201 and effects of LUM-201 administration on growth hormone release over time in children with idiopathic pediatric growth hormone deficiency (PGHD).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-03-17; most recent amendment 2023-10-03.
Status change: Recruiting → Active, Not Recruiting 2023-03-13
Status change: Not Yet Recruiting → Recruiting 2021-06-28
Trial Details
NCT Number NCT04806854
Lead Sponsor Lumos Pharma
Conditions Growth Hormone Deficiency
Enrollment 24 participants
Start Date 2021-07-14
Primary Completion 2030-04 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2023-10-04